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The survival of patients with hematological malignancies has been significantly improved due to the development of new 
therapeutic agents. However, relapse remains a major matter for concern. Recently, T cells engineered with chimeric antigen 
receptor (CAR) were reported to show unprecedented responses in a range of hematological malignancies. The persistence of 
the CAR-T cell can last for years and tends toward long-term antitumor memory by which relapses can be effectively prevent-
ed. The primary side effects that appear in most clinical trials are cytokine release syndrome and neurotoxicity. However, these 
symptoms can be treated and reversed. In this review, we describe CAR structure and function and summarize recent advances 
in CAR-T cell therapy in hematological malignancies. 
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BASIC CONCEPTS CONCERNING CAR  
Chimeric antigen receptor (CAR) is an artificial receptor 
consisting of a single-chain variable fragment (scFv), a 
hinge chain and a transmembrane and an intracellular signal 
region. In 1989, for the first time, Gross et al. generated and 
expressed chimeric T-cell receptor (TcR) genes composed 
of the TcR constant (C) domains fused to the antibody’s 
variable (V) domains (Gross et al., 1989). Compared with 
autologous T cells modified with tumor-specific T cell  
receptors (TCRs), CAR-T cells can overcome major 
histocompatibility complex (MHC) restriction and thus  
exhibit better anti-tumor activity. 
The scFv is the most important part of CAR because it 
determines the target. The ideal target antigen for CAR 
should be protein epitopes, carbohydrates and glycolipids 
presented on the tumor cell surface. Moreover, other anti-
gens such as lineage-specific antigens, highly expressed in 
tumor tissues can also be considered in special cases. 
Fully activated T cells require both a TCR signal and 
co-stimulatory signals, such as CD28, CD40L, and CD137, 
which are usually absent from tumor cells. Because of this, 
such co-stimulatory signals as CD28, OX40, CD40L, 
CD137 and CD27, were introduced into the intracellular 
CAR domain. This construction greatly improved T cell 
survival and cytokine secretion (Carpenito et al., 2009; 
Curran et al., 2015; Hombach et al., 2012).  
PROGRESS OF CAR-T THERAPY IN 
HEMATOLOGICAL MALIGNANCY 
Early breakthroughs in CAR-T  
Although genetically modified T cell therapy has been pre-
sent for many years, the efficiency of early genetically 
modified T cells was not satisfactory. Recently, the chimer-
ic antigen receptor modified T cell has garnered much at-
tention because a major breakthrough has been achieved. In 
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2011, three cases of chronic lymphoblastic leukemia (CLL), 
which were all refractory, and relapsed chronic B cell lym-
phocytic leukemias were treated with CD19 targeted 
CAR-T as reported by June and his workers (Kalos et al., 
2011; Porter et al., 2011). Two of the three patients were 
p53-deficient, which indicated a poor prognosis (Dohner et al., 
1995). After treatment, two patients achieved complete re-
mission (CR), and another achieved partial remission (PR). 
One of the CR patients received only a very low dose of 
CAR-T (1.46×105 kg1 CAR-T cells), but the treatment still 
showed excellent therapeutic efficiency at such a low dos-
age; 23 d after infusion, adenopathy was no longer present. 
A fluorescence in situ hybridization (FISH) test showed that 
P53 loss was negative, flow cytometry analysis showed that 
no CLL or B cells were detected, and 31 d after infusion, 
CT showed remission of the adenopathy. At the time the 
report was published, the remission had lasted for 10 
months (Porter et al., 2011). 
Well-designed clinical trials  
After June’s report of a CAR-T breakthrough in hemato-
logical malignancy, reports of modified T cell-related clini-
cal research in hematological malignancy increased, most of 
which applied to CD19-targeted CAR-T. In 2012, the na-
tional cancer research center reported eight cases of 
CD19-targeted CAR-T in the treatment of B cell malignan-
cies, for which the co-stimulation signal was CD28. All of 
the patients received chemotherapy before the CAR-T infu-
sion and received an IL-2 infusion after the CAR-T infu-
sion. Six patients achieved remission (Kochenderfer et al., 
2012). One year later, Brentjens et al. published the results 
of their clinical trial at the Memorial Sloan-Kettering Can-
cer Center on the treatment of five acute lymphocytic leu-
kemia (ALL) patients using CD19-targeted CAR-T with a 
CD28 co-stimulation signal. Chemotherapy was conducted 
before infusion and amazingly, the ALL patients achieved 
rapid depletion of leukemic cells and MRD (minimal resid-
ual disease negative)-complete remission; the start of the 
remission ranged from 8 to 59 d after the CAR-T infusion 
(Brentjens et al., 2013). In contrast to previous studies, 
Baylor College of Medicine enrolled and treated eight leu-
kemia patients using CD19-targeted CAR-T with a CD28 
co-stimulation signal. This was done without chemotherapy 
and before infusion. Two of the patients had already 
achieved CR before the CAR-T infusion, and among the 
other six patients, five showed a response to the CAR-T 
treatment (Cruz et al., 2013). using the same type of 
CAR-T, June et al. repeated their success in two children 
with ALL. About one month after infusion, both patients 
achieved morphological remission, and a clonal immuno-
globulin heavy chain (IGH) rearrangement test showed that 
remaining ALL cells were cleared. Unfortunately however, 
23 d after infusion, an IGH test found a malignant transfor-
mation in one child, and her leukemia relapsed two months 
after infusion. The relapsed cells were CD45dim+, CD34+ 
and CD19, so it was inferred that the malignant cells had 
escaped via a CD19-loss mutation. Fortunately, the other 
child experienced continued remission (Grupp et al., 2013).  
After 2014, studies with more cases began to be reported, 
and studies on the survival rate as well as a relapse analysis 
were also conducted. These studies mainly included re-
searches at the University of Pennsylvania, the Memorial 
Sloan-Kettering Cancer Center, the Baylor College of Medi-
cine and the National Cancer Institute (Table 1). Davila et al. 
reported fourteen complete remissions among sixteen patients 
with a CR rate of 88% (Davila et al., 2014). June et al. still 
used CD137 (4-1BB) as a co-stimulation signal and report-
ed twenty seven out of thirty treated patients had achieved 
complete remission, resulting in a CR rate of 90%. The con-
tinued event-free survival rate after six months was 67%, 
and the total survival rate was 78%. At the sixth month after 
infusion, the rate of the existence of CAR-T cells was 68%. 
In 27 patients, morphologically complete remission had 
been achieved at one month after infusion, and in twenty 
two patients, flow cytometry analysis detected no malignant 
residues. Two patients with leukemic cells detected in the 
spinal fluid had their central nervous system (CNS) malig-
nant cells eradicated after infusion and maintained complete 
remission beyond six months. The disease relapsed at six 
weeks to eight and a half months after infusion in seven CR 
patients. Among these seven, three patients were found to 
have lost their CAR-T cells two weeks to three months after 
infusion, and all of the remaining cells were CD19 positive. 
Four relapsed patients still maintained CAR-T cells. Along 
with normal B cell recovery from the second to third month, 
three patients relapsed. Three patients relapsed because of 
the loss of CD19 in the ALL cells. Among 27 CR patients, 
19 achieved durable remission, and 15 patients did not ac-
cept any other treatment (Maude et al., 2014b). In 2015, 
Rosenberg and his workers reported CAR-T with CD28 
treatment of B cell malignancies (Kochenderfer et al., 2015; 
Lee et al., 2015). Four complete remissions were achieved 
in seven diffuse large B lymphoma patients, and three of 
them achieved durable remission (beyond 9–22 months). 
All six chronic B cell malignant patients achieved complete 
or partial remission, and 3 of 4 CLL patients maintained 
long term remission. Among 20 ALL patients, eight had 
allogenic hemopoietic stem cell transplants before the 
CAR-T infusion, and 14 patients showed a response to the 
infusion; the reaction rate was 70% in which twelve patients 
achieved MRD-negative complete remission. The 10 
months event-free survival at a median follow-up of ten 
months in those patients was 51.6% at 9.7 months and  
beyond.  
Non-CD19 targeted CAR-T in hematological malignan-
cies 
Above, we discussed clinical trials conducted with CD19 
targeted CAR-T cells. Moreover, clinical trials of non- 
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CD19 CAR-T have also been explored (Table 2). Early in 
2012, a “third generation” of CD20-specific CAR-T with 
CD28 and 4-1BB costimulatory elements was generated to 
treat three patients with lymphoma after cyclophosphamide 
lymphodepletion. All three patients showed remission after 
infusion, and two remained progression-free for more than 
12 months (Till et al., 2012). In 2013, Ritchie et al. reported 
a trial of anti-LeY CAR-T coupled with CD28 in acute my-
eloid leukemia (AML). Following fludarabine-containing 
preconditioning, five patients were enrolled, and four pa-
tients received a cell infusion. Three of these four patients 
had evidence of a biological response to the CAR-T cell 
infusion, and one patient remained in remission for over 23 
months (Ritchie et al., 2013). In 2014, Wang et al. designed 
CD20-specific CAR-T cells coupled with CD137 and en-
rolled seven patients with lymphoma. Five patients achieved 
tumor regression, and one patient with no bulky tumor bur-
den attained ongoing complete remission for 14 months 
(Wang et al., 2014). Wang et al. reported another trial using 
anti-CD33 CAR-T and treated a 41-year-old male patient 
with AML. The patient showed a marked decrease of blasts 
in the bone marrow two weeks after therapy, but the disease 
had progressed at nine weeks after cell infusion (Wang et al., 
2015). Compared with CD19-targeted CAR-T, published 
data on non-CD19-targeted CAR-T clinical trials did not 
show the same excellent therapeutic efficiency, but did 
show that non-CD19 targeted CAR-T can make a difference 
in other hematological malignancies such as lymphoma and 
AML. Therefore, exploring better applications of CAR-T in 
non-B-cell-malignancies is an attractive and challenging 
field of study. 
From the discussion above, we can see that second gen-
eration CAR-T with a co-stimulation signal, especially 
CD19-targeted CAR-T, can act efficiently in the treatment 
of hematological malignancy. In many studies, the response 
rates to CAR-T are above 50%. We believe that CAR-T is a 
major breakthrough in cell therapy as well as in the treat-
ment of malignancies. Compared with the current therapies 
for hematological malignancy, CAR-T has more specific 
tumor-cytotoxicity and does not require a bone marrow 
match. However, monitoring and controlling side effects are 
still a disadvantage of clinical CAR-T applications. 
Side effects in treatment of hematological malignancies 
In general, CAR-T therapy is relatively safe for the treat-
ment of hematological malignancy. However, CAR-T did 
indeed exhibit some extended side effects, mostly syn-
dromes (Table 3). The primary side effect is cytokine re-
lease syndrome (CRS) also known as a cytokine storm, a 
syndrome caused by excessive cytokine release that is   
Table 1  Summary of the main clinical trials conducted in CD19+ hematological malignanciesa) 
Institution UPenn NCI MSKCC BCM 









CAR endodomain CD137+CD3 CD28+CD3 CD28+CD3 CD3 vs. CD28+CD3
CD19+ Disease ALL CLL ALL CLL NHL ALL CLL ALL CLL NHL 
Patients enrolled 44 52 24 14 
Preconditioning Variable Flu/Cy or appendix vs. none* Variable None 
Gene vector Lentivirus Retrovirus Retrovirus Retrovirus 
Infused CAR+ T cell number 1.4×107–1.1×109 4.0×105–3.0×107 kg1 1.8×108–3.2×109  2.0×107–2.0×108 m2§ 
Patients responded 35 33 15 6 
a) CAR, chimeric antigen receptor. UPenn, University of Pennsylvania. NCI, National Cancer Institute. MSKCC, Memorial Sloan-Kettering Cancer 
Center. BCM, Baylor College of Medicine. CLL, chronic lymphocytic leukemia. NHL, non-Hodgkin lymphoma. ALL, acute lymphoblastic leukemia. Flu, 
Fludarabine. Cy, cyclophosphamide. *, In the trial registered as NCT01087294, all 10 enrolled patients had undergone allogeneic hematopoietic stem cell 
transplantation (alloHSCT) and did not take any depleting chemotherapies before receiving CAR-T cells infusion.§, Number of total cells infused. 
Table 2  Summary of clinical trials conducted with non-CD19-targeted CAR-T in hematological malignancies 
Identifier Target Disease Status Institute Location
NCT02259556 CD30 Lymphoma recruiting Chinese PLA General Hospital China 
NCT01864902 CD33 Myeloid Leukemia recruiting 
NCT01886976 CD138 Multiple Myeloma recruiting 
NCT02274584 CD30 Lymphoma recruiting Peking University 
NCT01716364 LeY Multiple Myeloma; AML; Myelodysplastic Syn-
drome 
unknown Peter MacCallum Cancer Centre Australia
NCT02315612 CD22 Follicular Lymphoma; ALL; NHL; Large Cell 
Lymphoma 
recruiting National Cancer Institute  America 
NCT01316146 CD30 Non-Hodgkin’s Lymphoma; Hodgkin’s Lymphoma Active, not recruiting Baylor College of Medicine 
NCT02159495 CD123 AML recruiting City of Hope Medical Center 
NCT02546167 BCMA Multiple Myeloma recruiting Abramson Cancer Center of the 
University of Pennsylvania 
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Table 3  Case summary of the main toxicities reported in clinic trials that are currently conducteda) 
Institution NCI MSKCC Total 
Patients enrolled 52 24 76 
Fever 24 19 43 
Hypotension 13 8 21 
Hypoxia/ dyspnea 7 2 9 
Kidney toxicity 4 1 5 
Cardiac disorders 5 2 7 
Respiratory disorders 6 1 7 
Fatigue/rigors/ chills 3 7 10 
Dysphasia/ obtundation 9 6 15 
Headache 6 0 6 
a) Cytopenia is frequently discovered after depleting chemotherapy and is not listed here. All of the adverse events listed here are Grade 3 or Grade 4. In 
trials at UPenn, all of the patients with ALL developed CRS in which eight patients had severe CRS. They did not report details of adverse events; thus, 
those studies at UPenn are not listed here. Patients treated at BCM showed few adverse events and are also not listed here.  
usually observed in CAR-T-related therapy. In immuniza-
tion therapy, immune system activation can become uncon-
trolled, which leads to a clinical reaction such as a systemic 
inflammatory response. Other reported side effects include 
tumor lysis syndrome, myalgia, neurotoxicity, B cell defi-
ciency, capillary leak syndrome, respiratory distress syn-
drome, macrophage activation syndrome, diarrhea and co-
agulation disorders. 
DIAGNOSIS AND MANAGEMENT OF CRS 
Mild CRS does not require special treatment, but severe 
life-threatening CRS requires powerful intervention. Hence, 
the diagnosis and management of severe CRS are the key 
focuses of monitoring after infusion. Cytokines that were 
reported as significantly elevated after infusion are IFN-, 
IL-6, TNF-, IL-2, GM-CSF, IL-10, IL-8, IL-5, and frac-
talkine (Davila et al., 2014; Grupp et al., 2013; Kalos et al., 
2011; Kochenderfer et al., 2012). Three of these cytokines 
are thought to be highly related to CRS: IL-6, IFN- and 
TNF-. IL-6 is an anti-inflammatory cytokine that has mul-
tiple effects and is thought to be a central regulatory factor 
in CRS (Lee et al., 2014). TNF is a potent factor that induc-
es low blood pressure (Schiller et al., 1991). IFN- can in-
duce fever, fatigue and myalgia (Foon et al., 1985; 
Vadhan-Raj et al., 1986). Potentially life-threatening com-
plications of CRS include respiratory distress syndrome, 
cardiac dysfunction, neurologic toxicity, renal and/or hepat-
ic failure and disseminated intravascular coagulation. Cardiac 
failure should be paid special attention (Maude et al., 2014a). 
Severe CRS can transform into macrophage activation syn-
drome (Grupp et al., 2013). 
Knowing that excessive cytokine release is the cause of 
CRS, it is quite expected that we can predict CRS by moni-
toring cytokine levels. Considering that different individuals 
have different cytokine base values, it is better to compare 
increases in multiple cytokines instead of setting a threshold 
cytokine level. Brentjens et al. identified seven cytokines 
associated with CRS: IFN-, IL-5, IL-6, IL-10, Flt-3L, 
GM-CSF and fractalkine. They thought that CRS should be 
considered severe if two of the seven cytokines’ levels were 
elevated over 75-fold or one cytokine level was elevated 
over 250-fold. However, current clinical laboratory tests do 
not include all of these cytokines. Moreover, cytokine levels 
may be inconsistent with clinical signs because of the vari-
ous individual sensitivities. Thus, they considered C reac-
tion protein (CRP) as an ideal indicator. In their trails, 
if >20 mg dL1 was set as the threshold for CRS, the sensitiv-
ity was 86%, and the accuracy rate was 100% (Davila et al., 
2014). However, as an inflammatory factor, CRP can be 
affected by many factors and fluctuates frequently. The 
greatest interference is from infection, and it is difficult to 
distinguish infection from CRS using only CRP. In another 
study, only 50% of patients with CRP>20 mg dL1 showed 
serve CRS, and the authors suggested that the effectiveness 
of CRP in predicting CRS was associated with the CAR 
design (Maude et al., 2014b). 
Currently, no laboratory test can precisely predict and 
diagnose CRS or reliably judge the severity of CRS de-
pending on a patient’s clinical signs. An article about CRS 
contains a standard for CRS grading and principles for its 
management. Grade 1 CRS mainly presents as a fever and 
other mild constitutional symptoms; grade 2 CRS presents 
as low blood pressure, which can respond to a single pressor 
drug or fluid infusion, anoxia responsive to <40% oxygen 
and grade 2 organ toxicity; grade 3 CRS presents as low 
blood pressure that requires multiple or high doses of pres-
sor drugs, anoxia unresponsive to <40% oxygen and grade 3 
organ toxicity; grade 4 CRS presents as grade 4 organ tox-
icity that requires mechanical ventilation. Additionally, 
grade 3 and 4 CRS require the use of Tocilizumab or ster-
oids for symptomatic treatment (Maude et al., 2014a). 
Steroids always play an important role in immune related 
diseases, and this applies to CRS management. A current 
report indicates that CRS can be quickly resolved after the 
use of steroids (Brentjens et al., 2013; Maude et al., 2014b). 
However, steroids can greatly damage CAR-T cells and 
even eliminate them. Patients managed with steroids always 
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relapse, and the relapse will still respond to CAR-T cells 
(Brentjens et al., 2013; Davila et al., 2014). The IL-6 recep-
tor inhibitor Tocilizumab seems to be an excellent drug to 
resolve CRS without greatly affecting CAR-T cells. Expe-
rience with the clinical use of Tocilizumab has demonstrat-
ed good CRS control, and CRS remission usually occurs 
within 24 h (Davila et al., 2014; Grupp et al., 2013; Maude 
et al., 2014b). Other recommended drugs are anti-TNF- 
mAbs (infliximab), soluble TNF- receptor (etanercept) and 
IL-1R based inhibitors (anakinra) (Maude et al., 2014a).  
Factors affecting side effects of CAR-T and its solution 
Many factors may affect the side effects of CAR-T, and 
many factors still require more study. However, the plasma 
inflammatory cytokine level is definitely important. We 
surmise that the principal factors may be patient tumor load, 
infused cell dosage, chemotherapy before infusion, the pa-
tient’s sensitivity to cytokines and the type of co-stimula- 
tory signal. 
Most studies support the view that under a heavy tumor 
load, the risk of CRS is higher (Brentjens et al., 2013; 
Kochenderfer et al., 2012; Lee et al., 2015; Maude et al., 
2014b). Kochenderfer et al. suggested that the ratio of target 
cells should be decreased to reduce the risk of serious side 
effects induced by excessive cytokines, that is, treat patients 
with a lower tumor load or administer B cell-depleting 
pharmaceuticals such as Rituximab before cell infusion. A 
split-dosage and low infusion cell dosage are also recom-
mended (Kochenderfer et al., 2012). “Kochenderfer’s clini-
cal results also showed that in ALL patients who responded 
to treatment, those with heavy tumor loads were prone to 
present grade 3 to 4 CRS. In six patients in whom grade 3 
and higher CRS occurred, four patients showed the infiltra-
tion of over 50% malignant bone marrow cells. In those 
who did not respond to the CAR-T cells, none presented 
serious CRS, even with the infiltration of 95% malignant 
bone marrow cells. Brentjens et al. reported that cytokine 
elevation was directly associated with the tumor load and 
was also associated with fever after infusion. Two patients 
with the heaviest tumor load had the highest cytokine eleva-
tion. Four cytokines were the most elevated: sIL-2R, 
IFN-, IL-6 and IFN-inducible protein 10 (IP10). The two 
patients with the heaviest tumor load experienced continued 
fever and low blood pressure as well as transient changes in 
their mental state. Depleting chemotherapy before infusion 
was also suggested to reduce the tumor load (Brentjens et al., 
2013). In June’s clinical trial, all of the patients treated 
showed CRS, and 27% of the patients (8/30) had serious 
side effects, which were thought to be associated with the 
tumor load as well (Maude et al., 2014b). However, a low 
tumor load did not equal absolute safety. Two patients 
showed 3 grade CRS with the infiltration of 5% and 7.7% 
bone marrow malignant cells. A patient’s sensitivity to cy-
tokines must also be considered (Lee et al., 2015).  
The dosage of infused cells is also an important factor 
related to side effects. Especially in trials in which chemo-
therapy is given before infusion, the dosage can greatly in-
fluence the severity and the time of appearance of side ef-
fects. After drastic chemotherapy, the risk of severe CRS is 
greatly increased. In a death report, patients who did not 
receive depleting chemotherapy received a 1.2×107–3.0×107 
CAR-T cells kg1 infusion and did not respond to the thera-
py. Afterwards, one patient received two days of cyclo-
phosphamide chemotherapy and then received the same cell 
infusion dose as the three previous patients. The patient 
experienced drastic side effects that presented as sepsis-like 
low blood pressure and renal failure. Although the autopsy 
did not indicate that CAR-T cells were the direct cause of 
death, subsequent to that case, the infusion dosage was ad-
justed to 1/3 of the previous dosage and was split over two 
days. The new treatment regime was not as dangerous 
(Brentjens et al., 2011). Another case of death occurred 
several minutes after infusion with an order of magnitude of 
1010 cells (Morgan et al., 2010). In later clinical trials, dos-
age over 1010 was rarely reported. 
Compared with target differences, the effects of various 
co-stimulatory signals may play a more important role in 
side effects, although more studies are still necessary. The 
most used co-stimulatory signals are CD28 and CD137 
(4-1BB). In pre-clinical studies, it was observed that CD137 
caused less secretion of IL-2 and TNF- (Milone et al., 
2009), and in vivo IL-2 and TNF- did not significantly 
increase. So, the researchers indicated that using CD137 
instead of CD28 may be a strategy to reduce toxicity of cy-
tokines (Kalos et al., 2011). However, in clinical trials using 
these two co-stimulatory signals, severe side effects have 
been reported. In CLL patients, a reaction to cytokines with 
CD137 occurred slightly late, usually ten days later. As for 
CD28, side effects occurred more quickly, within 3–5 d 
(Brentjens et al., 2013). The differences in side effects and 
the time of occurrence due to co-stimulatory signal selection 
still need further study. 
Moreover, the different sensitivities of patients to cyto-
kines may offer an explanation as to why some patients 
presented severe CRS at a low tumor load and low infusion 
dosage. In a trial, one patient who developed severe CRS 
following CD19-CAR therapy for ALL was found to carry a 
mutation in the perforin gene. It is believed that this is what 
predisposed the patient to macrophage activation syndrome 
(HLH) (Lee et al., 2014). This suggests that different gene 
expression levels may have enormous influence. 
CAR-T related death 
Although CAR-T is thought to be a relatively safe treat-
ment, deaths in trials have still been reported. There have 
been three deaths reported in CAR-T related clinical  
trials (Brentjens et al., 2010; Kochenderfer et al., 2015;  
Morgan et al., 2010). The first death reported was a patient 
who received two days cyclophosphamide chemotherapy 
(1.5 g m2) before CAR-T infusion. After the CAR-T infu-
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sion, the patient presented low blood pressure, dyspnea and 
renal failure. 20 h after infusion the patient had a continued 
fever accompanied by low blood pressure. Then, acute renal 
failure appeared, and the patient became anuric. In intensive 
care unit (ICU), pressure support was conducted, and the 
low blood pressure was resolved. However, the anuria con-
tinued and was accompanied by a gradual increase of serum 
potassium and serum phosphate. The patient died four days 
after infusion. However, the autopsy did not indicate cyto-
kine release syndrome as the cause of death. Finally, the 
patient was thought to have died of infection after immuno-
suppression, instead of from the CAR-T therapy itself 
(Brentjens et al., 2010). In 2015, Rosenberg reported a 
death case in which CD19-targeted CAR-T cells with CD28 
were used. The patient died of an unknown cause 16 d after 
infusion without any symptoms of cytokine release syn-
drome. Considering that the patient had underlying cardiac 
disease, the cause of death was thought to be a heart disor-
der, so the CAR-T therapy had no relationship to the cause 
of death (Kochenderfer et al., 2015). Another death case 
report was directly related to CAR-T but did not occur with 
a hematological malignancy. Morgan et al. designed an 
ERBB2 targeted CAR-T with CD28, 4-1BB and CD3 sig-
nal molecules. A patient with a colon cancer metastasis in 
the lungs and liver received a CAR-T infusion at a dosage 
of 1010 in which 79% of the cells were CAR-T cells. The 
patient immediately exhibited respiratory failure 15 min 
after infusion, and chest radiography indicated an exudate in 
the lungs. The patient died 5 d after the infusion. During the 
progression of side effects, the cytokines were elevated; 
therefore, the cause of death was thought to be directly re-
lated to CAR-T. It seems that pulmonary epithelial cells 
also express a small amount of ERBB2 and thus are at-
tacked by CAR-T cells (Morgan et al., 2010). Therefore, in 
the treatment of hematological malignancy, no cases of 
death were reported as directly caused by the CAR-T ther-
apy itself. However, caution must be taken to prevent infec-
tion during treatment. 
FACTORS AFFECTING THE THERAPEUTIC 
EFFECT OF CAR-T 
Lymphocyte-depleting chemotherapy before infusion  
The role of depleting chemotherapy before CAR-T cell in-
fusion has been gradually recognized for the following rea-
sons: (i) to reduce the tumor load and thus decrease the risk 
of severe side effects and (ii) to deplete some lymphocytes 
and secure enough proliferation space for the infused 
CAR-T cells (Cui et al., 2009; Kohn et al., 2011). A study 
revealed that lymphatic clearance is closely related to ther-
apeutic effects (Wrzesinski et al., 2010). In a trial that 
aimed to compare the therapeutic efficiency between the 
first and second generation CAR-T, all six NHL patients did 
not receive chemotherapy before infusion. No patients 
showed obvious reaction to either first or second generation 
CAR-T therapy (Savoldo et al., 2011). We previously dis-
cussed the death case reported by Brentjens et al. Patients 
who did not receive depleting chemotherapy before infusion 
did not show an objective reaction to CAR-T, but a fourth 
patient had drastic side effects at the same dose of CAR-T 
cells because the patientreceived two days of cyclophos-
phamide chemotherapy before infusion. After the death, the 
other patients continued to receive pre-infusion chemother-
apy but at a lower dose. Then, the patients began to achieve 
remission (Brentjens et al., 2011). This suggests an associa-
tion between side effects and therapeutic effects. Brentjens 
showed no relationship between CRS and anti-tumor effi-
ciency (Brentjens et al., 2013). However in Rosenberg’s 
trial, patients who experienced the best therapeutic effi-
ciency all presented CRS (Kochenderfer et al., 2013). 
Maude et al. also suggested that some degree of CRS might 
be necessary for the anti-tumor effect (Maude et al., 2014b). 
The relation between CAR-T therapy and the anti-tumor 
effect still requires further study. When selecting a chemo-
therapy strategy, a balance must be struck: mild chemo-
therapy limits proliferation of CAR-T cells, while, on the 
other hand, drastic chemotherapy may drive CAR-T cells to 
proliferate too quickly and increase the risk of severe CRS. 
The design of CAR influences the efficacy of treatment 
The long-term existence of CAR-T cells (>4 weeks) and a 
high interferon- (peak value >200 pg mL1) are associated 
with better clinical outcomes (Xu et al., 2013). In patients 
who achieved continued remission, CAR-T cells and their 
proliferation can always be stably detected. (Maude et al., 
2014b). The longest time of CAR-T endurance reported was 
over four years (Porter et al., 2015), and the persistence of 
CD19-targeted CAR-T is always accompanied by a loss of 
B cells. Because many relapsed patients have B cell recov-
ery, it is an important consideration to extend the time of 
CAR-T cell persistence to prevent relapse. The addition of a 
co-stimulatory signal caused the second generation CAR-T 
cell breakthrough as compared with the first generation 
CAR-T cells. Second generation cells with a CD28 
co-stimulatory signal stably proliferated two weeks after 
infusion, but CAR-T cells without a co-stimulatory signal 
did not proliferate and disappeared after six weeks. 
(Savoldo et al., 2011). At present, CD28 and CD137 
(4-1BB) are the two signals used most commonly and it is 
found that they exhibit good therapeutic effects. Different 
studies yield diverse opinions about these two signals. In 
Brentjens’s pre-clinical research, the anti-tumor effect  
of CD137 co-stimulatory was not as good as CD28 
(Brentjens et al., 2007; Zhong et al., 2010). However, in 
other studies, CD137 was thought to have better persistence 
and tumor-cytotoxicity. To verify the respective advantages 
of these two signals, more clinical research is still neces-
sary. 
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Cytokine is a double-edged sword 
Although excessive cytokines are the main cause of CRS, 
cytokines play an important role in the function of CAR-T 
cells. IL-2 can improve the proliferation of T cells  
(Caserta et al., 2010), and CAR-T cells able to secrete IL-2 
and IL-15 were demonstrated to have better tu-
mor-cytotoxicity in pre-clinical experiments (Hoyos et al., 
2010; Pegram et al., 2012). IL-2 facilitated tumor-specific T 
cells to generate IFN- (Overwijk et al., 2003), and IFN- 
was highly related to CAR-T tumor-cytotoxicity. Therefore, 
a clinical strategy was to infuse IL-2 after infusing CAR-T 
cells; among eight patients thus treated, six patients 
achieved remission (Kochenderfer et al., 2012). Neverthe-
less, in many clinical trials later, clinicians did not adminis-
ter IL-2 after CAR-T infusion and still good remission was 
achieved. A study indicated that the use of exogenous IL-2 
had no relationship with CAR-T cell persistence and prolif-
eration (Xu et al., 2013). This may be because CAR-T cells 
themselves can secrete cytokines. Thus, whether exogenous 
cytokines are necessary and which cytokines may be neces-
sary still require further study. 
A heavy tumor load may decrease the therapeutic effect 
We have previously indicated that a heavy tumor load is 
related to a higher risk of side effects. A heavy tumor load 
may play a negative role on the therapeutic effect of 
CAR-T. A study observed that patients with a heavy tumor 
load were more likely to eliminate their infused CAR-T 
cells as compared with those with a lower tumor load. This 
phenomenon seems contradictory to the phenomenon that 
CAR-T cells proliferate better under antigen stimulation 
(Brentjens et al., 2011). Moreover, another study indicated 
that a heavy tumor load may render CAR-T treatment inef-
fective (Lee et al., 2015). The necessity of targeted cells for 
the maintenance of CAR-T cell numbers was also men-
tioned in another study (Kalos et al., 2011). However, why a 
heavy tumor load made CAR-T cells prone to elimination 
under antigen stimulation was not definitely explained. 
FUTURE STUDIES  
We have mentioned the breakthrough of second generation 
CAR-T in hematological malignancy. The important role of 
CAR-T therapy is becoming more greatly recognized by 
researchers. In many trials, the remission rate can be above 
50% as compared with the Food and Drug Administration 
(FDA) approved conventional treatment for refractory ALL 
in which the complete remission rate is below 25%. At pre-
sent, chemotherapy for leukemia treatment has serious side 
effects and limited tumor-cytotoxicity. Hematopoietic stem 
cell transplantation requires a bone marrow match and is 
expensive. CAR-T therapy is a targeted therapy which does 
not require a bone marrow match. It is highly efficient and 
specifically kills malignant cells. Another advantage is that 
CAR-T cells can persist in vivo and therefore preserve the 
ability to prevent a recurrence. It is highly possible that, in 
addition to chemotherapy and hematopoietic stem cell 
transplantation, CAR-T can become a conventional treat-
ment in hematological malignant disease. However, the role 
of CAR-T is currently uncertain. Whether it should be used 
as an independent therapy or as a bridge between chemo-
therapy and hematopoietic stem cell transplantation still 
needs further study.  
The efficiency and side effects seem mutually antagonis-
tic, and balancing them is a key challenge. Based on expe-
rience acquired in early CAR-T trials, it is believed that 
chemotherapy before infusion which can both reduce the 
tumor burden and deplete lymphocytes, decreasing the cell 
dose infused and a split-dose infusion strategy might be the 
most direct ways to guarantee safety without overly affect-
ing tumor-cytotoxicity. Considering that CAR-T cells pre-
serve their proliferation ability in vivo, a high cell dose does 
not seem necessary. A dosage of 105 cells kg1 has even 
been reported as effective. On the cellular level, optimizing 
the structure of the co-stimulatory signal and target as well 
as including suicide genes might also improve security and 
efficiency.  
Whether the great improvement of CAR-T therapy in 
hematological malignancies can also be replicated in solid 
tumors is a question worth considering. However, CAR-T 
does not achieve the same success in solid tumors as it does 
in hematological malignancies. Summarizing the results for 
hematological malignant disease, relevant factors might be: 
(i) solid tumor cells are more concentrated than hematolog-
ical malignant cells, so the contact surface between the ma-
lignant cells and CAR-T cells may be limited; (ii) solid tu-
mors contain a heavy immunosuppressive environment, and 
the penetration of CAR-T cells into solid tumors is limited; 
(iii) no specific target is present in solid tumors. 
In the context of “precision medicine”, CAR-T can act as 
a terminal stage in precision medicine practice. At present, 
CAR-T cells are designed with a standard target, but differ-
ent patients have various types of mutant cells. Rooted in an 
analysis of large data and patient sequence data, designing a 
particular CAR-T for each individual patient could create 
more precise CAR-T with high tumor-cytotoxicities. Such a 
strategy could make CAR-T therapy a powerful treatment in 
malignant disease.  
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